BioXplor was founded in January 2017 and is backed by UC Berkeley Skydeck, Merck & European Innovation Council (Horizon 2020) accelerators, amongst other investment partners. The 10 person strong team has combined expertise in computer science and biomedical science applied to drug discovery, which are the core components of what we do, in equal measure. We are passionate about developing data-driven approaches to accelerate and improve Life Science R&D. Cofounders: Mark Rogers, MSc (Molecular Biotech) is CEO and has a over 15 years experience in emerging biotechnology, in industry and academia, including gene editing applications, membrane protein-protein screening, cell based gene therapy. He was previously Associate Director, Emerging Biotechnology Initiative (Europe) at Merck KgaA. Pavel Kartasevs, MEng (Computer Engineering), MSc (Bioinformatics) is CTO, and has a specialised CompBio background combining high performance computing, bioinformatics and software engineering. He previously worked on bioinformatics and machine learning research at Cranfield University. Anna O'Leary, BA (Economics & Finance) is COO, and brings management, finance and business operations expertise to the team. At Aramark she won an award for change management and team building, and worked at RBS Global Markets in the US in trading floor operations.